31.62
-0.71 (-2.20%)
| Penutupan Terdahulu | 32.33 |
| Buka | 31.76 |
| Jumlah Dagangan | 335,724 |
| Purata Dagangan (3B) | 599,161 |
| Modal Pasaran | 1,565,345,024 |
| Harga / Jualan (P/S) | 3.43 |
| Harga / Buku (P/B) | 3.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jul 2025 - 1 Aug 2025 |
| Margin Keuntungan | -7.95% |
| Margin Operasi (TTM) | -4.82% |
| EPS Cair (TTM) | -0.810 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 13.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 17.03% |
| Nisbah Semasa (MRQ) | 4.11 |
| Aliran Tunai Operasi (OCF TTM) | 22.19 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -10.42 M |
| Pulangan Atas Aset (ROA TTM) | -3.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -8.38% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Instruments & Supplies (US) | Menurun | Bercampur |
| Medical Instruments & Supplies (Global) | Menurun | Menurun | |
| Stok | AtriCure, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | -3.5 |
| Purata | -1.38 |
|
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. |
|
| Sektor | Healthcare |
| Industri | Medical Instruments & Supplies |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 3.36% |
| % Dimiliki oleh Institusi | 103.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 60.00 (JMP Securities, 89.75%) | Beli |
| 60.00 (Citizens Capital Markets, 89.75%) | Beli | |
| Median | 55.00 (73.94%) | |
| Rendah | 44.00 (Needham, 39.15%) | Beli |
| Purata | 53.33 (68.66%) | |
| Jumlah | 6 Beli | |
| Harga Purata @ Panggilan | 31.68 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| JMP Securities | 30 Apr 2025 | 60.00 (89.75%) | Beli | 29.91 |
| Needham | 30 Apr 2025 | 44.00 (39.15%) | Beli | 29.91 |
| 27 Mar 2025 | 51.00 (61.29%) | Beli | 34.37 | |
| UBS | 30 Apr 2025 | 58.00 (83.43%) | Beli | 29.91 |
| Citizens Capital Markets | 02 Apr 2025 | 60.00 (89.75%) | Beli | 34.13 |
| Canaccord Genuity | 28 Mar 2025 | 52.00 (64.45%) | Beli | 31.83 |
| JP Morgan | 27 Mar 2025 | 46.00 (45.48%) | Beli | 34.37 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 23 May 2025 | Pengumuman | AtriCure to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference |
| 29 Apr 2025 | Pengumuman | AtriCure Reports First Quarter 2025 Financial Results |
| 10 Apr 2025 | Pengumuman | AtriCure Announces First Use of the AtriClip PRO-Mini® Device |
| 08 Apr 2025 | Pengumuman | AtriCure to Announce First Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |